Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.

CONCLUSIONS: These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer.
PMID: 23386691 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 5, 2013 Category: Cancer & Oncology Authors: Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang GD, Guo X, Bao L, Guoting Q, Deng X, Li Q, Erm D, Sakamoto JH, Liu X, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G Tags: Clin Cancer Res Source Type: research